6533b85bfe1ef96bd12ba1f0
RESEARCH PRODUCT
When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?
David NavarroJosé Luis PiñanaEugenio GimenezCarlos SolanoVíctor VinuesaJuan Carlos Hernández-boludaPaula Amatsubject
AdultMaleAdolescentCongenital cytomegalovirus infectionCytomegalovirusHematologic Neoplasms03 medical and health sciences0302 clinical medicinemedicineHumansProspective StudiesProgenitor cellProspective cohort studyAgedTransplantationbusiness.industryAntiviral therapyHematologyMiddle Agedmedicine.diseaseAllograftsTransplantationGraft-versus-host disease030220 oncology & carcinogenesisHematologic NeoplasmsImmunologyCytomegalovirus InfectionsFemaleStem cellbusiness030215 immunologyStem Cell Transplantationdescription
When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?
year | journal | country | edition | language |
---|---|---|---|---|
2017-06-06 | Bone marrow transplantation |